Cosmo Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Lainate Italy (1997)
Status: Acquired by Salix (2014) → now Bausch Health Companies (2015)

Organization Overview

First Clinical Trial
2003
NCT00061035
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aries srl | Aries srl (ARIES) | Cosmo Bioscience

Active Ingredients

Drugs in Phase 3 Trials (1)

methylene blue (proveblue) (2 trials)

Drugs in Phase 2 Trials (3)

allogeneic adipose derived mesenchymal stem cell (1 trial)

cb-10-01 (1 trial)

rifamycin (aemcolo) (2 trials)

Drugs in Phase 1 Trials (1)

transgenic lymphocyte immunization vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 3)

Diarrhea (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Melanoma (Phase 2)

Osteoarthritis (Phase 2)

Prostatic Neoplasms (Phase 1)

Skin Neoplasms (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5